Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LlcfiledCriticalBayer Healthcare Llc
Priority to MYPI20070790priorityCriticalpatent/MY151329A/en
Publication of MY151329ApublicationCriticalpatent/MY151329A/en
THIS INVENTION RELATES TO FACTOR VIII MUTEINS THAT ARE COVALENTLY BOUND, AT A PREDEFINED SITE THAT IS NOT AN N-TERMINAL AMINE, TO ONE OR MORE BIOCOMPATIBLE POLYMERS SUCH AS POLYETHYLENE GLYCOL. THE MUTEIN CONJUGATES RETAIN VIII PROCOAGULANT ACTIVITY AND HAVE IMPROVED PHARMACOKINETIC PROPERTIES.
MYPI200707902007-05-182007-05-18Site-directed modification of fviii
MY151329A
(en)
Linear and cross-linked high molecular weight polysilanes, polygermanes, and copolymers thereof, compositions containing the same, and methods of making and using such compounds and compositions
Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases